Kole Roybal

Kole Roybal has advanced synNotch and other synthetic receptor technologies to program custom therapeutic responses in engineered T cells for solid tumor targeting. His work demonstrates that synthetic receptors can direct T cells to produce specific therapeutic payloads only upon encountering tumor antigens. He has developed next-generation synthetic receptor platforms that expand the therapeutic logic programmable into immune cells.